Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP2-CAR-NK in Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT05922930Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TROP2-CAR-NK in ovarian cancer, mesonephric-like adenocarcinoma (MLAC), pancreatic cancer (PC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2023; status: active, not recruiting.
02
Drugs
TROP2-CAR-NK
03
Conditions
ovarian cancermesonephric-like adenocarcinoma (MLAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05922930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922930.